Search

Your search keyword '"Veelken, Kaya"' showing total 16 results
Start Over Author "Veelken, Kaya"
16 results on '"Veelken, Kaya"'

1. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group

Author

Havasi, Andrea, Heybeli, Cihan, Leung, Nelson, Angel-Korman, Avital, Sanchorawala, Vaishali, Cohen, Oliver, Wechalekar, Ashutosh, Bridoux, Frank, Jaffer, Insara, Gutgarts, Victoria, Hassoun, Hani, Levinson, Maya, Rosenbaum, Cara, Milani, Paolo, Palladini, Giovanni, Merlini, Giampaolo, Hegenbart, Ute, Schönland, Stefan, Veelken, Kaya, Pogrebinsky, Alexander, Doros, Gheorghe, and Landau, Heather

Published
2022
Full Text
View/download PDF

2. Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis

Author

Muchtar, Eli, primary, Dispenzieri, Angela, additional, Wisniowski, Brendan, additional, Palladini, Giovanni, additional, Milani, Paolo, additional, Merlini, Giampaolo, additional, Schönland, Stefan, additional, Veelken, Kaya, additional, Hegenbart, Ute, additional, Geyer, Susan M., additional, Kumar, Shaji K., additional, Kastritis, Efstathios, additional, Dimopoulos, Meletios A., additional, Liedtke, Michaela, additional, Witteles, Ronald, additional, Sanchorawala, Vaishali, additional, Szalat, Raphael, additional, Landau, Heather, additional, Petrlik, Erica, additional, Lentzsch, Suzanne, additional, Coltoff, Alexander, additional, Bladé, Joan, additional, Cibeira, Maria Teresa, additional, Cohen, Oliver, additional, Foard, Darren, additional, Wechalekar, Ashutosh, additional, and Gertz, Morie A., additional

Published
2023
Full Text
View/download PDF

3. Two-Year Evaluation of the German Clinical Amyloidosis Registry

Author

Hegenbart, Ute, primary, Fuhr, Niklas, additional, Huber, Laura, additional, Kimmich, Christoph, additional, Veelken, Kaya, additional, Dittrich, Tobias, additional, Ziehl, Rita, additional, aus dem Siepen, Fabian, additional, Carpinteiro, Alexander, additional, Hansen, Timon, additional, Müller-Tidow, Carsten, additional, Benner, Axel, additional, and Schönland, Stefan, additional

Published
2021
Full Text
View/download PDF

4. Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Author

Muchtar, Eli, primary, Wisniowski, Brendan, additional, Palladini, Giovanni, additional, Milani, Paolo, additional, Merlini, Giampaolo, additional, Schönland, Stefan, additional, Veelken, Kaya, additional, Hegenbart, Ute, additional, Dispenzieri, Angela, additional, Kumar, Shaji, additional, Leung, Nelson, additional, Kastritis, Efstathios, additional, Dimopoulos, Meletios A., additional, Liedtke, Michaela, additional, Witteles, Ronald, additional, Sanchorawala, Vaishali, additional, Szalat, Raphael, additional, Landau, Heather J, additional, Petrlik, Erica, additional, Lentzsch, Suzanne, additional, Coltoff, Alexander, additional, Bladé, Joan, additional, Cibeira, M. Teresa, additional, Cohen, Oliver C, additional, Foard, Darren, additional, Gillmore, Julian D, additional, Lachmann, Helen J, additional, Wechalekar, Ashutosh D., additional, and Gertz, Morie A., additional

Published
2021
Full Text
View/download PDF

5. Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Author

Muchtar, Eli, primary, Dispenzieri, Angela, additional, Wisniowski, Brendan, additional, Palladini, Giovanni, additional, Milani, Paolo, additional, Merlini, Giampaolo, additional, Schönland, Stefan, additional, Veelken, Kaya, additional, Hegenbart, Ute, additional, Kumar, Shaji, additional, Kastritis, Efstathios, additional, Dimopoulos, Meletios A., additional, Liedtke, Michaela, additional, Witteles, Ronald, additional, Sanchorawala, Vaishali, additional, Szalat, Raphael, additional, Landau, Heather J, additional, Petrlik, Erica, additional, Lentzsch, Suzanne, additional, Coltoff, Alexander, additional, Bladé, Joan, additional, Cibeira, M. Teresa, additional, Cohen, Oliver, additional, Foard, Darren, additional, Wechalekar, Ashutosh D., additional, and Gertz, Morie A., additional

Published
2021
Full Text
View/download PDF

6. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow‐up

Author

Basset, Marco, primary, Kimmich, Christoph R., additional, Schreck, Nicholas, additional, Krzykalla, Julia, additional, Dittrich, Tobias, additional, Veelken, Kaya, additional, Goldschmidt, Hartmut, additional, Seckinger, Anja, additional, Hose, Dirk, additional, Jauch, Anna, additional, Müller‐Tidow, Carsten, additional, Benner, Axel, additional, Hegenbart, Ute, additional, and Schönland, Stefan O., additional

Published
2021
Full Text
View/download PDF

7. Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21

Author

Kimmich, Christoph R., primary, Terzer, Tobias, additional, Benner, Axel, additional, Hansen, Timon, additional, Carpinteiro, Alexander, additional, Dittrich, Tobias, additional, Veelken, Kaya, additional, Jauch, Anna, additional, Huhn, Stefanie, additional, Basset, Marco, additional, Goldschmidt, Hartmut, additional, Müller‐Tidow, Carsten, additional, Schönland, Stefan O., additional, and Hegenbart, Ute, additional

Published
2021
Full Text
View/download PDF

8. Gain 1q21 Is an Adverse Prognostic Factor in Patients with Relapsed/Refractory AL Amyloidosis Treated with Lenalidomide and Dexamethasone

Author

Basset, Marco, primary, Kimmich, Christoph, additional, Dittrich, Tobias, additional, Veelken, Kaya, additional, Goldschmidt, Hartmut, additional, Hose, Dirk, additional, Seckinger, Anja, additional, Jauch, Anna, additional, Mueller-Tidow, Carsten, additional, Hegenbart, Ute, additional, and Schönland, Stefan, additional

Published
2020
Full Text
View/download PDF

9. Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression

Author

Basset, Marco, primary, Hummedah, Kamal, additional, Kimmich, Christoph, additional, Veelken, Kaya, additional, Dittrich, Tobias, additional, Brandelik, Simone, additional, Kreuter, Michael, additional, Hassel, Jessica, additional, Bosch, Nikolaus, additional, Stuhlmann‐Laeisz, Christiane, additional, Blank, Norbert, additional, Müller‐Tidow, Carsten, additional, Röcken, Christoph, additional, Hegenbart, Ute, additional, and Schönland, Stefan, additional

Published
2020
Full Text
View/download PDF

10. Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL

Author

Korell, Felix, primary, Laier, Sascha, additional, Sauer, Sandra, additional, Veelken, Kaya, additional, Hennemann, Hannah, additional, Schubert, Maria-Luisa, additional, Sauer, Tim, additional, Pavel, Petra, additional, Mueller-Tidow, Carsten, additional, Dreger, Peter, additional, Schmitt, Michael, additional, and Schmitt, Anita, additional

Published
2020
Full Text
View/download PDF

11. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

Author

Kimmich, Christoph R., primary, Terzer, Tobias, primary, Benner, Axel, primary, Dittrich, Tobias, primary, Veelken, Kaya, primary, Carpinteiro, Alexander, primary, Hansen, Timon, primary, Goldschmidt, Hartmut, primary, Seckinger, Anja, primary, Hose, Dirk, primary, Jauch, Anna, primary, Wörner, Stefan, primary, Beimler, Jörg, primary, Müller-Tidow, Carsten, primary, Hegenbart, Ute, primary, and Schönland, Stefan O., primary

Published
2020
Full Text
View/download PDF

12. Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia

Author

Dittrich, Tobias, primary, Benner, Axel, additional, Kimmich, Christoph, additional, Siepen, Fabian aus dem, additional, Veelken, Kaya, additional, Kristen, Arnt V., additional, Bochtler, Tilmann, additional, Katus, Hugo A., additional, Müller-Tidow, Carsten, additional, Hegenbart, Ute, additional, and Schönland, Stefan O., additional

Published
2019
Full Text
View/download PDF

14. Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.

Author

Muchtar, Eli, Dispenzieri, Angela, Wisniowski, Brendan, Palladini, Giovanni, Milani, Paolo, Merlini, Giampaolo, Schönland, Stefan, Veelken, Kaya, Hegenbart, Ute, Geyer, Susan M, Kumar, Shaji K, Kastritis, Efstathios, Dimopoulos, Meletios A, Liedtke, Michaela, Witteles, Ronald, Sanchorawala, Vaishali, Szalat, Raphael, Landau, Heather, Petrlik, Erica, and Lentzsch, Suzanne

Published
2022
Full Text
View/download PDF

16. Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.

Author

Muchtar E, Wisniowski B, Geyer S, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Leung N, Dispenzieri A, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Ulloa P, Sanchorawala V, Szalat R, Dooley K, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Gillmore J, Lachmann H, Wechalekar A, and Gertz MA

Abstract

Importance: Kidney light chain (AL) amyloidosis is associated with a risk of progression to kidney replacement therapy (KRT) and death. Several studies have shown that a greater reduction in proteinuria following successful anticlonal therapy is associated with improved outcomes., Objective: To validate graded kidney response criteria and their association with kidney and overall survival (OS)., Design, Setting, and Participants: This retrospective, multicenter cohort was conducted at 10 referral centers for amyloidosis from 2010 to 2015 and included patients with kidney AL amyloidosis that was evaluable for kidney response and who achieved at least hematologic partial response within 12 months of diagnosis. The median follow-up was 69 (54-88) months. Data analysis was conducted in 2023., Exposure: Four kidney response categories based on the reduction in pretreatment 24-hour urine protein (24-hour UP) levels: complete response (kidCR, 24-hour UP ≤200 mg), very good partial response (kidVGPR, >60% reduction in 24-hour UP), partial response (kidPR, 31%-60% reduction), and no response (kidNR, ≤30% reduction). Kidney response was assessed at landmark points (6, 12, and 24 months) and best kidney response., Main Outcomes and Measures: Cumulative incidence of progression to KRT and OS., Results: Seven-hundred and thirty-two patients (335 women [45.8%]) were included, with a median (IQR) age of 63 (55-69) years. The median (IQR) baseline 24-hour proteinuria and estimated glomerular filtration rate was 5.3 (2.8-8.5) g per 24 hours and 72 (48-92) mL/min/1.73m2, respectively. In a competing-risk analysis, the 5-year cumulative incidence rates of progression to KRT decreased with deeper kidney responses as early as 6 months from therapy initiation (11%, 12%, 2.1%, and 0% for kidNR, kidPR, kidVGPR, and kidCR, respectively; P = .002) and were maintained at 12 months and 24 months and best kidney response. Patients able to achieve kidCR/kidVGPR by 24 months and at best response had significantly better OS compared with kidPR/kidNR. Kidney progression, defined as a 25% or greater decrease in estimated glomerular filtration rate, was associated with cumulative incidence of progression to KRT and OS., Conclusions and Relevance: The results of this cohort study suggest that graded kidney response criteria offers clinically and prognostically meaningful information for treating patients with kidney AL amyloidosis. The response criteria potentially inform kidney survival based on the depth of reduction in 24-hour proteinuria levels and demonstrate an OS advantage for those able to achieve kidCR/kidVGPR compared with kidPR/kidNR. Taken together, achievement of at least kidVGPR by 12 months is needed to ultimately improve kidney and patient survival.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results